Mounjaro vs Zepbound: Same Drug, Different Labels

Tirzepatide

1 molecule, 2 brands

Mounjaro and Zepbound contain identical tirzepatide. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for chronic weight management and obstructive sleep apnea.

Eli Lilly and Company

Eli Lilly and Company

View as image

Mounjaro and Zepbound are the same molecule. Both contain tirzepatide, a once-weekly injectable peptide that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. Both are manufactured by Eli Lilly. Both come in the same dose strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg). The difference is regulatory: Mounjaro received FDA approval in May 2022 for type 2 diabetes, while Zepbound received FDA approval in November 2023 for chronic weight management in adults with obesity or overweight with at least one weight-related condition. In December 2024, Zepbound also received approval for moderate-to-severe obstructive sleep apnea in adults with obesity. Understanding why Eli Lilly created two brand names for the same peptide requires understanding how pharmaceutical regulation, insurance coverage, and clinical evidence intersect.

Why Two Brand Names?

The answer is regulatory and financial, not pharmacological. The FDA approves drugs for specific indications. A drug approved for diabetes cannot be marketed for weight loss under the same approval. If Eli Lilly wanted tirzepatide available for both conditions with separate marketing, separate clinical trial programs, and separate insurance billing codes, it needed separate brand names.

This practice is not unique to tirzepatide. Semaglutide follows the same pattern: Ozempic for type 2 diabetes, Wegovy for weight management. Liraglutide was Victoza for diabetes and Saxenda for obesity.

The two-brand strategy also creates distinct insurance pathways. Many health insurance plans cover diabetes medications but exclude or restrict weight management drugs. By separating the brands:

• A patient with type 2 diabetes can receive Mounjaro under their pharmacy benefit for diabetes
• A patient with obesity but no diabetes can seek Zepbound coverage under obesity treatment benefits (where available)
• Off-label prescribing (using Mounjaro for weight loss in a non-diabetic patient, or Zepbound for diabetes) may result in insurance denial

What Tirzepatide's Dual Mechanism Does

Tirzepatide is a 39-amino-acid synthetic peptide that activates both the GIP receptor and the GLP-1 receptor. This dual agonism distinguishes it from semaglutide and liraglutide, which activate only GLP-1 receptors.

GLP-1 receptor activation reduces appetite, slows gastric emptying, and stimulates insulin secretion in a glucose-dependent manner. GIP receptor activation adds complementary metabolic effects: enhanced insulin secretion, improved fat metabolism, and potentially direct effects on adipose tissue and brain circuits controlling food intake.

Bernardi and colleagues' 2026 network meta-analysis of 28 RCTs encompassing 34,367 participants directly compared tirzepatide against semaglutide at their maximum doses (15 mg and 2.4 mg, respectively). Tirzepatide demonstrated superiority across every measured outcome:^[1]

These advantages apply to both brands equally because they contain the same molecule.

The Clinical Evidence Base

For Diabetes (Mounjaro)

The SURPASS clinical trial program established tirzepatide's efficacy for type 2 diabetes. SURPASS-2 directly compared tirzepatide against semaglutide 1 mg (the diabetes dose) and found tirzepatide produced greater HbA1c reductions and more weight loss at all tested doses. Cardiovascular outcomes data published in 2026 showed tirzepatide reduced major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.^[2]

For Weight Management (Zepbound)

The SURMOUNT trial program tested tirzepatide specifically for obesity in patients without diabetes. SURMOUNT-1 showed an average weight loss of 20.9% at the highest dose (15 mg) over 72 weeks. SURMOUNT-2 tested tirzepatide in patients with both obesity and type 2 diabetes, finding 14.7% weight loss.

For Sleep Apnea (Zepbound)

SURMOUNT-OSA demonstrated that tirzepatide reduced the apnea-hypopnea index (the standard measure of sleep apnea severity) by approximately 50% in patients with moderate-to-severe obstructive sleep apnea and obesity, leading to the additional Zepbound indication.

Real-World Data

Two 2026 multicenter studies confirm that tirzepatide's clinical trial results translate to routine practice.

Angelopoulos and colleagues studied 115 adults with obesity (no diabetes) treated with low-dose tirzepatide (2.5 mg for 4 weeks, then 5 mg for 8 weeks) in a prospective multicenter study. At 12 weeks, mean body weight decreased by 8.2 kg (-7.3%), with 46.1% achieving at least 5% weight loss. HbA1c, LDL cholesterol, and triglycerides all improved. Nausea was the most common side effect (7.8%), and treatment discontinuation occurred in 10.4%.^[3]

Barrea and colleagues reported similar findings from Italian obesity clinics: 70 adults with obesity received tirzepatide 2.5 mg then 5 mg, with dose-dependent reductions in body weight, BMI, and waist circumference (P < 0.001 for all). Improvements in cholesterol, triglycerides, fasting glucose, insulin, and liver enzymes were observed even at these starting doses.^[4]

What Happens When You Stop

The SURMOUNT-4 withdrawal study provides the clearest picture of what happens after discontinuation. Horn and colleagues analyzed 308 tirzepatide-treated participants who switched to placebo after achieving 10% or more weight loss.^[5]

Within one year of stopping tirzepatide, most participants regained 25% or more of lost weight. The critical finding: cardiometabolic improvements reversed proportionally to weight regain.

• Patients regaining less than 25% of lost weight maintained most metabolic gains (waist +0.8 cm, blood pressure +6.8 mmHg)
• Patients regaining 75% or more lost nearly all benefits (waist +14.7 cm, blood pressure +10.4 mmHg, HbA1c +0.35%)

This proportional reversal applies regardless of whether the patient was prescribed Mounjaro or Zepbound. The clinical implication: tirzepatide treats obesity and diabetes but does not cure them. Like antihypertensive medication, the benefits persist only while the drug is continued.

Dosing: Identical Across Both Brands

Both Mounjaro and Zepbound follow the same dose escalation schedule:

The 4-week minimum at each step exists to reduce gastrointestinal side effects. Most clinical trial data showing maximum weight loss used the 10 mg or 15 mg doses over 36-72 weeks.

Side Effects: Same Drug, Same Profile

Because Mounjaro and Zepbound are chemically identical, their side effect profiles are identical:

• Gastrointestinal: nausea (most common, especially during dose escalation), diarrhea, vomiting, constipation, abdominal pain
• Metabolic: hypoglycemia (primarily in diabetes patients using concurrent insulin or sulfonylureas)
• Injection site: reactions at the injection site
• Body composition: tirzepatide reduces both fat mass and lean mass; the body composition effects are an area of ongoing study

Serious but uncommon risks include pancreatitis, gallbladder disease, and a potential medullary thyroid carcinoma signal (black box warning based on rodent data, not confirmed in humans).

The Practical Decision

For patients, the Mounjaro versus Zepbound question reduces to three factors:

Diagnosis. If you have type 2 diabetes, Mounjaro is the on-label option. If you have obesity without diabetes, Zepbound is on-label. Having both conditions could qualify for either.

Insurance. Coverage varies dramatically. Some plans cover Mounjaro for diabetes but deny Zepbound for obesity. Some plans cover both. Some cover neither. The list price for both brands is approximately $1,000-1,100 per month without insurance. Eli Lilly offers savings programs that reduce out-of-pocket costs for eligible commercially insured patients.

Availability. Compounding pharmacies have filled supply gaps for semaglutide, but tirzepatide's patent protection and supply chain are managed differently. Both brands have experienced supply constraints since launch. Zepbound at certain dose strengths has been intermittently unavailable. When one brand is out of stock, pharmacies cannot substitute the other because they carry different NDC (National Drug Code) numbers despite containing the same molecule.

Cardiovascular Evidence

Tirzepatide's cardiovascular outcomes data has strengthened the case for both brands. The SURPASS-CVOT (cardiovascular outcomes trial) demonstrated a reduction in major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.^[2]

This matters for the Mounjaro vs Zepbound discussion because cardiovascular risk reduction is relevant to both diabetic and obese populations. Patients with obesity carry elevated cardiovascular risk even without diabetes, and the SURMOUNT program showed improvements in blood pressure, lipids, and inflammatory markers alongside weight loss. Whether the cardiovascular benefit applies equally in a non-diabetic obese population (the Zepbound indication) has not been separately established in a dedicated outcomes trial, but the mechanistic basis is consistent.

The cardiovascular data also influences prescribing decisions and insurance formulary placement. Drugs with demonstrated cardiovascular benefit receive preferred formulary status at many insurance plans, potentially improving access for both brand names.

The Japanese Subpopulation

An analysis of Japanese participants in the tirzepatide program showed that efficacy and safety in this East Asian population were consistent with the broader trial results.^[6] This is relevant because BMI thresholds for obesity treatment in Asian populations (BMI 25+) differ from Western thresholds (BMI 30+), and confirming tirzepatide's effectiveness across ethnic populations supports global applicability of both brand names.

Comparing to Semaglutide

The most common clinical comparison is tirzepatide versus semaglutide. The Bernardi network meta-analysis provides the most comprehensive comparison to date: tirzepatide produced 6.10% greater weight loss and 0.33% greater HbA1c reduction than semaglutide across 28 RCTs.^[1] Both drugs require ongoing use to maintain benefits. Both carry gastrointestinal side effects. The choice between them depends on individual response, insurance formulary, and prescriber preference. For patients who respond well to semaglutide (Ozempic/Wegovy), switching to tirzepatide may not provide enough additional benefit to justify disruption. For patients who plateau on semaglutide or do not reach their weight or glycemic targets, tirzepatide offers a mechanistically distinct option with demonstrated superior efficacy in pooled analyses. For patients starting treatment, the network meta-analysis data favors tirzepatide, but access, cost, and availability may determine the practical choice.

The Bottom Line

Mounjaro and Zepbound are the same tirzepatide molecule at the same doses, manufactured by the same company. The only difference is the FDA-approved indication: diabetes for Mounjaro, obesity and sleep apnea for Zepbound. A 2026 network meta-analysis of 34,367 participants confirmed tirzepatide's superiority over semaglutide for both weight loss and glycemic control. Real-world data from two 2026 multicenter studies validates clinical trial results at lower doses. The SURMOUNT-4 withdrawal analysis showed that stopping tirzepatide leads to proportional reversal of metabolic benefits within one year. For patients, the brand name is determined by diagnosis and insurance coverage, not by any pharmacological difference.

Frequently Asked Questions

Is Mounjaro the same as Zepbound?

Yes. Both Mounjaro and Zepbound contain the same active ingredient (tirzepatide), are made by Eli Lilly, and come in the same dose strengths (2.5 mg to 15 mg). The only difference is the FDA-approved indication: Mounjaro for type 2 diabetes, Zepbound for chronic weight management and obstructive sleep apnea in adults with obesity.

Why does tirzepatide have two brand names?

FDA regulations require separate approvals for different medical indications. Eli Lilly needed a separate brand name to market tirzepatide for obesity (Zepbound) versus diabetes (Mounjaro). This also creates distinct insurance billing pathways: diabetes coverage for Mounjaro, obesity coverage for Zepbound.

Which is better for weight loss, Mounjaro or Zepbound?

Neither is better because they are the same drug. A patient taking Mounjaro 15 mg receives the same molecule at the same dose as a patient taking Zepbound 15 mg. The SURMOUNT trials showing up to 20.9% weight loss used tirzepatide, the molecule in both brands.

Is tirzepatide better than semaglutide?

A 2026 network meta-analysis of 28 RCTs (34,367 participants) found tirzepatide produced 6.10% greater weight loss and 0.33% greater HbA1c reduction than semaglutide at their maximum doses. Both drugs are effective; tirzepatide's dual GIP/GLP-1 mechanism appears to provide an additional benefit over semaglutide's GLP-1-only mechanism.

How much does Mounjaro or Zepbound cost?

The list price for both brands is approximately $1,000 to $1,100 per month without insurance. With commercial insurance, copays vary from $25 (with savings programs) to several hundred dollars. Coverage depends on the diagnosis and insurance plan. Some plans cover Mounjaro for diabetes but exclude Zepbound for obesity.

What happens if you stop taking tirzepatide?

The SURMOUNT-4 withdrawal study showed that most patients regained 25% or more of lost weight within one year of stopping. Metabolic improvements (blood pressure, HbA1c, cholesterol) reversed proportionally to weight regain. Patients who maintained the most weight had the best metabolic outcomes. Current evidence supports continued use for sustained benefits.